A mouse model of chronic idiopathic pulmonary fibrosis

Physiological Reports

Volumn 2, Issue 2, 2014, Pages 1-8

  Limjunyawong, Nathachit ^a   Mitzner, Wayne ^a   Horton, Maureen R ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bleomycin; Chronic idiopathic pulmonary fibrosis; Diffusing capacity; Idiopathic pulmonary fibrosis; Pulmonary function; Quantitative histology

Indexed keywords

EID: 84924803828     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.1002/phy2.249     Document Type: Article

References (30)

1. Adamson, I. Y., and D. H. Bowden. 1974. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am. J. Pathol. 77:185–197.
2. Borzone, G., R. Moreno, R. Urrea, M. Meneses, M. Oyarzun, and C. Lisboa. 2001. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 163:1648–1653.
3. Bowden, D. H. 1984. Unraveling pulmonary fibrosis: the bleomycin model. Lab. Invest. 50:487–488.
4. Chaudhary, N. I., A. Schnapp, and J. E. Park. 2006. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am. J. Respir. Crit. Care Med. 173:769–776.
5. Chua, F., J. Gauldie, and G. J. Laurent. 2005. Pulmonary fibrosis: searching for model answers. Am. J. Respir. Cell Mol. Biol. 33:9–13.
6. Chung, M. P., M. M. Monick, N. Y. Hamzeh, N. S. Butler, L. S. Powers, and G. W. Hunninghake. 2003. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. Am. J. Respir. Cell Mol. Biol. 29:375–380.
7. Degryse, A. L., H. Tanjore, X. C. Xu, V. V. Polosukhin, B. R. Jones, F. B. McMahon, et al. 2010. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 299:L442–L452.
8. Ewart, S., R. Levitt, and W. Mitzner. 1995. Respiratory system mechanics in mice measured by end-inflation occlusion. J. Appl. Physiol. 79:560–566.
9. Ezzie, M. E., M. G. Piper, C. Montague, C. A. Newland, J. M. Opalek, C. Baran, et al. 2011. Thrombospondin-1-deficient mice are not protected from bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 44:556–561.
10. Fallica, J., S. Das, M. Horton, and W. Mitzner. 2011. Application of carbon monoxide diffusing capacity in the mouse lung. J. Appl. Physiol. 110:1455–1459.
11. Gharaee-Kermani, M., K. Hatano, Y. Nozaki, and S. H. Phan. 2005. Gender-based differences in bleomycin-induced pulmonary fibrosis. Am. J. Pathol. 166:1593–1606.
12. Goldstein, R. H., E. C. Lucey, C. Franzblau, and G. L. Snider. 1979. Failure of mechanical properties to parallel changes in lung connective tissue composition in bleomycin-induced pulmonary fibrosis in hamsters. Am. Rev. Respir. Dis. 120:67–73.
13. Hantos, Z., B. Daroczy, B. Suki, S. Nagy, and J. J. Fredberg. 1992. Input impedance and peripheral inhomogeneity of dog lungs. J. Appl. Physiol. 72:168–178.
14. Harrison, J. H. Jr, and J. S. Lazo. 1987. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J. Pharmacol. Exp. Ther. 243:1185–1194.
15. Hsia, C. C., D. M. Hyde, M. Ochs, and E. R. Weibel. 2010. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am. J. Respir. Crit. Care Med. 181:394–418.
16. Izbicki, G., M. J. Segel, T. G. Christensen, M. W. Conner, and R. Breuer. 2002. Time course of bleomycin-induced lung fibrosis. Int. J. Exp. Pathol. 83:111–119.
17. Lawson, W. E., V. V. Polosukhin, G. T. Stathopoulos, O. Zoia, W. Han, K. B. Lane, et al. 2005. Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin. Am. J. Pathol. 167:1267– 1277.
18. Moeller, A., K. Ask, D. Warburton, J. Gauldie, and M. Kolb. 2008. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell. Biol. 40:362–382.
19. Moore, B. B., and C. M. Hogaboam. 2008. Murine models of pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 294:L152–L160.
20. Moore, B., W. E. Lawson, T. D. Oury, T. H. Sisson, K. Raghavendran, and C. M. Hogaboam. 2013. Animal models of fibrotic lung disease. Am. J. Respir. Cell Mol. Biol. Mouratis, M. A., and V. Aidinis. 2011. Modeling pulmonary fibrosis with bleomycin. Curr. Opin. Pulm. Med. 17:355– 361.
21. Phan, S. H., R. S. Thrall, and C. Williams. 1981. Bleomycin-induced pulmonary fibrosis. Effects of steroid on lung collagen metabolism. Am. Rev. Respir. Dis. 124:428– 434.
22. Rydell-Tormanen, K., K. Andreasson, R. Hesselstrand, J. Risteli, D. Heinegard, T. Saxne, et al. 2012. Extracellular matrix alterations and acute inflammation; developing in parallel during early induction of pulmonary fibrosis. Lab. Invest. 92:917–925.
23. Scherle, W. 1970. A simple method for volumetry of organs in quantitative stereology. Mikroskopie 26:57–60.
24. Schneider, J. P., and M. Ochs. 2013. Stereology of the lung. Methods Cell Biol. 113:257–294.
25. Snider, G. L., B. R. Celli, R. H. Goldstein, J. J. O’Brien, and E. C. Lucey. 1978. Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Lung volumes, volume-pressure relations, carbon monoxide uptake, and arterial blood gas studied. Am. Rev. Respir. Dis. 117:289–297.
26. Soutiere, S. E., and W. Mitzner. 2004. On defining total lung capacity in the mouse. J. Appl. Physiol. 96:1658–1664.
27. Thrall, R. S., and P. Scalise. 1995. Bleomycin. Marcel Dekker, New York.
28. Vasilescu, D. M., Z. Gao, P. K. Saha, L. Yin, G. Wang, B. Haefeli-Bleuer, et al. 2012. Assessment of morphometry of pulmonary acini in mouse lungs by nondestructive imaging using multiscale microcomputed tomography. Proc. Natl Acad. Sci. USA 109:17105–17110.
29. Weibel, E. R. 1963. Morphometry of the human lung. Academic Press, New York.
30. Wilson, M. S., S. K. Madala, T. R. Ramalingam, B. R. Gochuico, I. O. Rosas, A. W. Cheever, et al. 2010. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207:535–552.